175 related articles for article (PubMed ID: 37439176)
1. [Prediction of 1p/19q codeletion status in diffuse lower-grade glioma using multimodal MRI radiomics].
Lu M; Qu Y; Ma A; Zhu J; Zou X; Lin G; Li Y; Liu X; Wen Z
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jun; 43(6):1023-1028. PubMed ID: 37439176
[TBL] [Abstract][Full Text] [Related]
2. Amide proton transfer weighted and diffusion weighted imaging based radiomics classification algorithm for predicting 1p/19q co-deletion status in low grade gliomas.
Ma A; Yan X; Qu Y; Wen H; Zou X; Liu X; Lu M; Mo J; Wen Z
BMC Med Imaging; 2024 Apr; 24(1):85. PubMed ID: 38600452
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric MR radiomics in brain glioma: models comparation to predict biomarker status.
He J; Ren J; Niu G; Liu A; Wu Q; Xie S; Ma X; Li B; Wang P; Shen J; Wu J; Gao Y
BMC Med Imaging; 2022 Aug; 22(1):137. PubMed ID: 35931979
[TBL] [Abstract][Full Text] [Related]
4. T2-FLAIR mismatch sign and machine learning-based multiparametric MRI radiomics in predicting IDH mutant 1p/19q non-co-deleted diffuse lower-grade gliomas.
Tang WT; Su CQ; Lin J; Xia ZW; Lu SS; Hong XN
Clin Radiol; 2024 May; 79(5):e750-e758. PubMed ID: 38360515
[TBL] [Abstract][Full Text] [Related]
5. Non-invasive genotype prediction of chromosome 1p/19q co-deletion by development and validation of an MRI-based radiomics signature in lower-grade gliomas.
Han Y; Xie Z; Zang Y; Zhang S; Gu D; Zhou M; Gevaert O; Wei J; Li C; Chen H; Du J; Liu Z; Dong D; Tian J; Zhou D
J Neurooncol; 2018 Nov; 140(2):297-306. PubMed ID: 30097822
[TBL] [Abstract][Full Text] [Related]
6. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
7. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
8. Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients.
Su C; Xu S; Lin D; He H; Chen Z; Damen FC; Ke C; Lv X; Cai K
Eur Radiol; 2022 Jan; 32(1):101-111. PubMed ID: 34272981
[TBL] [Abstract][Full Text] [Related]
9. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
[TBL] [Abstract][Full Text] [Related]
10. Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of
Park YW; Han K; Ahn SS; Choi YS; Chang JH; Kim SH; Kang SG; Kim EH; Lee SK
AJNR Am J Neuroradiol; 2018 Apr; 39(4):693-698. PubMed ID: 29519794
[TBL] [Abstract][Full Text] [Related]
11. Radiogenomics of lower-grade gliomas: machine learning-based MRI texture analysis for predicting 1p/19q codeletion status.
Kocak B; Durmaz ES; Ates E; Sel I; Turgut Gunes S; Kaya OK; Zeynalova A; Kilickesmez O
Eur Radiol; 2020 Feb; 30(2):877-886. PubMed ID: 31691122
[TBL] [Abstract][Full Text] [Related]
12. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
[TBL] [Abstract][Full Text] [Related]
13. Thin-Slice Magnetic Resonance Imaging-Based Radiomics Signature Predicts Chromosomal 1p/19q Co-deletion Status in Grade II and III Gliomas.
Kong Z; Jiang C; Zhang Y; Liu S; Liu D; Liu Z; Chen W; Liu P; Yang T; Lyu Y; Zhao D; You H; Wang Y; Ma W; Feng F
Front Neurol; 2020; 11():551771. PubMed ID: 33192984
[No Abstract] [Full Text] [Related]
14.
Zaragori T; Oster J; Roch V; Hossu G; Chawki MB; Grignon R; Pouget C; Gauchotte G; Rech F; Blonski M; Taillandier L; Imbert L; Verger A
J Nucl Med; 2022 Jan; 63(1):147-157. PubMed ID: 34016731
[TBL] [Abstract][Full Text] [Related]
15. Radiomics-Based Method for Predicting the Glioma Subtype as Defined by Tumor Grade, IDH Mutation, and 1p/19q Codeletion.
Li Y; Ammari S; Lawrance L; Quillent A; Assi T; Lassau N; Chouzenoux E
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406550
[TBL] [Abstract][Full Text] [Related]
16. MRI radiomics analysis of molecular alterations in low-grade gliomas.
Shofty B; Artzi M; Ben Bashat D; Liberman G; Haim O; Kashanian A; Bokstein F; Blumenthal DT; Ram Z; Shahar T
Int J Comput Assist Radiol Surg; 2018 Apr; 13(4):563-571. PubMed ID: 29270916
[TBL] [Abstract][Full Text] [Related]
17. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
18. Development and external validation of a non-invasive molecular status predictor of chromosome 1p/19q co-deletion based on MRI radiomics analysis of Low Grade Glioma patients.
Casale R; Lavrova E; Sanduleanu S; Woodruff HC; Lambin P
Eur J Radiol; 2021 Jun; 139():109678. PubMed ID: 33848780
[TBL] [Abstract][Full Text] [Related]
19. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
20. Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm.
van der Voort SR; Incekara F; Wijnenga MMJ; Kapas G; Gardeniers M; Schouten JW; Starmans MPA; Nandoe Tewarie R; Lycklama GJ; French PJ; Dubbink HJ; van den Bent MJ; Vincent AJPE; Niessen WJ; Klein S; Smits M
Clin Cancer Res; 2019 Dec; 25(24):7455-7462. PubMed ID: 31548344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
